Tumoral Angiogenesis: Review of the Literature

REFERENCES

• Kerbel R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006; 312: 1171–5
   PubMed Web of Science ®Google Scholar
• Khosravi P. Angiogenesis y neoplasias. Ann. Med. Interna. 2006; 23: 355–6
   Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature 1997; 386(6626)671–4
   PubMed Web of Science ®Google Scholar
• Ferrara N., Gerber H. P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9(6)669–76
   PubMed Web of Science ®Google Scholar
• Veikkola T., Karkkainen M., Claesson-Welsh L., et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000; 60(2)203–12
   PubMed Web of Science ®Google Scholar
• Shim W. S., Ho I. A., Wong P. E., Angiopoietin A. TIE(d) Balance in Tumor Angiogenesis. Mol. Cancer Res. 2007; 5(7)655–65
   PubMed Web of Science ®Google Scholar
• Kumar R., Yoneda J., Bucana C. D., et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int. J. Oncol. 1998; 12(4)749–57
   PubMed Web of Science ®Google Scholar
• Pugh C. W., Ratcliffe P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003; 90(6)677–84
   Google Scholar
• Harris AL. Hypoxia—a key regulatory factor in tumor growth. Nat. Rev. Cancer 2002; 2002(2)1–38
   Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007; 6(4)273–86
   PubMed Web of Science ®Google Scholar
• Takahashi Y., Tucker S. L., Kitadai Y., et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 1997; 1997(132)7–541
   Google Scholar
• Willett C. G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004; 10(2)145–7
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N. Engl. J. Med. 2004; 2004(350)23–2335
   Google Scholar
• Sandler A., Gray R., Perry M. C., et al. Paclitaxel—Carboplatin Alone or with Bevacizumab for Non—Small-Cell Lung Cancer. N. Engl. J. Med. 2006; 2006(355)24–2542
   Google Scholar
• Segerstrom L., Fuchs D., Bäckman U., Holmquist K., Christofferson R., Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr. Res. 2006; 60(5)576–81
   PubMed Web of Science ®Google Scholar
• Abrams T. J., Lee L. B., Murray L. J., et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003; 2003(2)5–471
   Google Scholar
• Mendel D. B., Laird A. D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003; 2003(9)1–327
   Google Scholar
• O'Farrell A. M., Abrams T. J., Yuen H. A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 2003(101)9–3597
   Google Scholar
• Iliopoulos O., Levy A. P., Jiang C., et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U S A 1996; 93(20)10595–9
   PubMed Web of Science ®Google Scholar
• Maxwell P. H., Wiesener M. S., Chang G. W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 1999(399)6733–271
   Google Scholar
• Na X., Wu G., Ryan C. K., et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol. 2003; 2003(170)2–588
   Google Scholar
• Motzer R. J., Hutson T. E., Tomczak P., et al. Sunitinib versus Interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007; 2007(356)2–115
   Google Scholar
• Lyons J. F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001; 8(3)219–25
   PubMed Web of Science ®Google Scholar
• Ratain M. J., Eisen T., Stadler W. M., , Phase I I, et al. placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006; 24(16)2505–12
   PubMed Web of Science ®Google Scholar
• Escudier B., Eisen T., Stadler W. M., et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N. Engl. J. Med. 2007; 2007(356)2–125
   Google Scholar
• Rini B., Rixe O., Bukowski R., et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. 2005; 4509, (Abstr)
   PubMedGoogle Scholar
• Drevs J., Muller-Driver R., Wittig C., et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002; 2002(62)14–4015
   Google Scholar
• Laquente B., Vinals F., Germa J. R. Metronomic chemotherapy: an antiangiogenic scheduling. Clin. Transl. Oncol. 2007; 9(2)93–8
   PubMed Web of Science ®Google Scholar
• Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol. 2001; 2(12)733–40
   PubMed Web of Science ®Google Scholar
• Orlando L., Cardillo A., Rocca A., et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer. Drugs 2006; 2006(17)8–961
   Google Scholar
• Orlando L., Cardillo A., Ghisini R., et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patioents with Her-2 positive metastatic breast cancer. BMC Cancer 2006; 2006(6)5–225
   Google Scholar